GSK Ends Deal For Anacor’s Antibiotic, Returns Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.
You may also be interested in...
Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time
Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.
Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time
Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.